c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
Biostem outlines $10M-$12M annual cash opex cuts as it targets in-house manufacturing in H1 2027
Seeking Alpha | Nov 12, 2026 7:20 PM EST
Read original article